SampleGelInformation:

Overview:

Activationofthezymogen,factorX,byeithertheintrinsicorextrinsicfactorXasecomplexesproducestheactiveserineproteasefactorXa(1,2).TheactivationoffactorXrequiresproteolyticcleavageoftheheavychain,resultinginthereleaseofanactivationglycopeptide.TheheavychainregioninfactorXacontainstheserineproteasecatalyticdomain,whilethelightchain,asinthezymogen,containsthemembranebindingdomain.

FactorXaparticipatesintheprothrombinasecomplex,whichcatalyzestherapidconversionofprothrombintothrombin.ProthrombinaseisanenzymecomplexcomposedoffactorXa(enzyme)andfactorVa(cofactor)assembledonacellularsurfaceinthepresenceofcalciumions.AlthoughfactorXacanindependentlycatalyzetheactivationofprothrombin,therateatwhichthisreactionoccursisincreasednearly300,000-foldwithcompleteassemblyoftheprothrombinasecomplex.TheclottingactivityoffactorXainvivoisterminatedbyeitherinactivationofthecofactor,factorVa,orbydirectinhibitionoffactorXabyinhibitors,suchasATIII,afterdisassemblyoftheprothrombinasecomplex.

Inrecentyears,molecularBIOLOGistshaveutilizedfactorXaforsitespecificcleavageoffusionproteinsexpressedinbacteria(9-12).AfactorXa-sensitivesiteisincorporatedbetweentherecombinantproteinofinterestandpeptidesorproteinswhichfacilitatepurificationand/orexpression.ThetargetproteinisreleasedfromtheexpressedhybridbycleavagewithfactorXa.ThefactorXacanthenbeeasilyremovedbyaffinitychromatography.

FactorXaispreparedbyactivatingpurifiedfactorXwiththefactorXactivatorisolatedfromRussell"svipervenom.FactorXaispurifiedfromtheactivationmixturebychromatographyoverbenzamidine-Sepharosefollowedbygelfiltration(1,3).SeveralmodifiedformsoffactorXaarealsoavailableincluding:A)active-siteblockedfactorXacontainingeitherthetripeptidechloromethylketoneinhibitorEGRck,orthefluorescentinhibitorDansyl-EGRck;andB)humanGla-domainlessβ-factorXa.Theenzymeissuppliedin50%(vol/vol)glycerol/H2Oandshouldbestoredat-20°C.PurityisdeterminedbySDS-PAGEanalysisandactivityismeasuredinafactorXaclottingassayand/orchromogenicsubstrateassay.

InadditiontoitsbroadapplicationincoagulationresearchfactorXacanbeusedforsitespecificcleavageoffusionproteins.AfactorXasensitivesiteisincorporatedbetweentherecombinantproteinofinterestandpeptidesorproteinswhichfacilitatepurificationand/orexpression.ThetargetproteinisreleasedfromtheexpressedhybridbycleavagewithfactorXa.FactorXacanthenbeeasilyremovedbyaffinitychromatography.LottolotconsistencyensuresreproducIBLeresultseverytime.Forexperimentsinvolvingcellcultures,pleasecontactustodiscusscustom,lowendotoxinlotsdesignatedforcellcultureuse.

Properties:

Haemtech生物制药服务（HBS）是一家领先的，符合cGMP要求的QC测试实验室，专门为生产重组和血浆衍生蛋白疗法的生物制药制造商提供分析服务，重点是那些会影响止血系统的药物。HBS使客户能够满足法规和质量测试要求，从而将其候选药物从开发转向商业化。

对生物制药的需求正在增长，并且该行业正在迅速采用外包策略，以作为满足不断升级的监管要求的一种方式。凭借在止血方面的丰富经验，HBS能够很好地协助开发影响凝血系统的药物产品。